Author No. of Patients Induction Therapy Maintenance Therapy Acute Rejection at 1 year Patient Survival Graft Survival Infections Other
Brennan et al. [7] 141 137 rATG Basiliximab Csa MMF Prednisone rATG: 15.6%

Basiliximab:

25.5% P=0.02
At 1 year: rATG: 95.7% Basiliximab: 95.6% No significant difference At 1 year: rATG: 90.8% Basiliximab: 89.8% No significant difference rATG: 85.8% Basiliximab: 75.2% P=0.03 No difference in incidence of cancer between the groups
Cantarovich et al. [57] 99 CSWD 98 CCS rATG rATG Csa MMF +/- prednisone At 1 year: CSWD: 17.3% CCS: 7.1% P=0.031 At 1 year: CSWD: 97.1% CCS: 99.0% No significant difference At 1 year: CSWD: 94.9% CCS: 93.2% No significant difference At 1 year: CSWD: 67.3% CCS: 72.8% No significant difference The CCS group had a trend towards a higher incidence of malignancy at 1 year (P=0.059).
Cianco et al. [59] 100 100 rATG/DAC rATG/C1H FK EC-MPS rATG/DAC: 11% rATG/C1H: 9%

No significant difference
At 4 years: rATG/DAC: 96% rATG/C1H: 92% No significant difference At 4 years: rATG/DAC: 91% rATG/C1H: 83% No significant difference At 1 year: rATG/DAC: 22% rATG/C1H: 21% No significant difference No cases of PTLD occurred in either group
Hanaway et al. [51] 251: 70 high risk 164 low risk 69   171 C1H (high and low risk patients) rATG (high risk patients only) Basiliximab (low risk patients only) FK MMF Early steroid withdrawal Low risk patients: C1H vs. basiliximab (3 vs. 20, P<0.001) High risk patients: C1H vs. rATG (11 vs. 13, P=0.53) At 3 years: C1H 96% Basiliximab 98% rATG 91% No significant difference At 3 years: C1H 95% Basiliximab 94% rATG 91% No significant difference Serious Events at 3 years Low risk (P=0.02): C1H 35% Basiliximab 22 High risk (P=0.009): C1H 60% rATG 80% Incidence of cancer was significantly higher in the C1H group compared to rATG or basiliximab (P=0.03)
Lebranchu et al. [33] 50 50 rATG Basiliximab Csa MMF Prednisone (withdrawn at 6 months) rATG: 8% Basiliximab: 10% No significant difference At 1 year: rATG: 100% Basiliximab: 98% No significant difference At 1 year: rATG: 96% Basiliximab: 94% No significant difference At 1 year: rATG: 86.0% Basiliximab: 64.7% No significant difference No cases of cancer occurred in either group
Mourad et al. [35] 53 52 rATG Basiliximab Csa MMF Prednisone rATG: 9.4% Basiliximab: 9.6% No significant difference At 1 year: rATG: 98.1% Basiliximab: 98.1% No significant difference At 1 year: rATG: 96.2% Basiliximab: 94.2% No significant difference At 1 year: rATG: 53.0% Basiliximab: 42.3% No significant difference No cases of PTLD occurred in either group
Woodle et al. [37] CSWD group (n=191) CCS group (n=195)   rATG 125 CSWD 136 CCS IL-2RA 66 CSWD 59 CCS   FK MMF +/- prednisone CSWD: rATG: 14.4% Basiliximab: 24.2% P=0.09 At 5 years: CSWD: 17.8% CCS: 10.8% P=0.058 At 5 years: CSWD: 94.2% CCS: 93.3% At 5 years: CSWD: 94.2% CCS: 96.4% CSWD: 39.3% CCS: 44.1%

No significant difference
No difference in incidence of cancer between the CSWD and CCS groups
Table 2: Summary of Induction Therapy Trials and Agent Comparisons.